IRVINE, Calif. / Oct 09, 2025 / Business Wire / Masimo (NASDAQ: MASI) today announced it will host a meeting with the analyst and investor community at 9:00am PT on Wednesday, December 3, 2025.
Presentations will be led by select members of the Executive Leadership Team and will cover an overview of the company’s business, market opportunities, innovation pipeline, commercial growth strategy, and long-term financial outlook.
The company invites investors to join the event via live webcast, which will be available on the Investor Relations section of its website at https://investor.masimo.com/ under “Events and Presentations” or directly by visiting the following link: Masimo Investor Day webcast. A replay of the webcast and the related slide presentations will be available on the company’s website following the event. In-person attendance is by invitation only and registration will be required.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, automation and connectivity solutions. Our mission is for Masimo innovations to empower clinicians to transform patient care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.
| Last Trade: | US$145.78 |
| Daily Change: | -3.47 -2.32 |
| Daily Volume: | 420,588 |
| Market Cap: | US$7.830B |
November 04, 2025 October 07, 2025 September 17, 2025 September 11, 2025 August 28, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load